News & Analysis as of

Investment Healthcare Pharmaceutical Industry

McDermott Will & Emery

HPE Europe 2024: Key Takeaways

McDermott Will & Emery on

On 19 September 2024, we were once again delighted to assemble hundreds of healthcare professionals, investors, and industry changemakers at The Langham  in London for our annual Healthcare Private Equity (HPE) Europe...more

A&O Shearman

Key takeaways from the LSX World Congress USA

A&O Shearman on

On September 11-12, we had the pleasure of attending the LSX World Congress USA in Boston, where leaders discussed the challenges and opportunities of M&A and partnerships in the pharmaceutical sector....more

Bass, Berry & Sims PLC

Healthcare Trends & Transactions Q2 2024

Bass, Berry & Sims PLC on

Deal volume across the healthcare industry generally appears to have steadied despite headwinds. The general sentiment is that buyers have adapted to the current interest rates and are gritting their teeth and pressing...more

Bass, Berry & Sims PLC

Key Takeaways from 2024 Asembia Specialty Pharmacy Summit

Bass, Berry & Sims PLC on

Asembia’s 20th Annual Specialty Pharmacy Summit once again brought investors and operators in the specialty pharmacy ecosystem to Las Vegas for learning sessions and networking. Bass, Berry & Sims brought a team of four...more

Fenwick & West Life Sciences Group

In 2024, the Digital Health Revolution Continues

Digital health is showing signs of life despite financial markets that seem determined to bring some of 2023’s volatility into the new year. Stocks are up and down, and bond yields are climbing. Inflation is proving stubborn,...more

Bass, Berry & Sims PLC

2024 Healthcare Private Equity Outlook & Trends

W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity. As we begin 2024, we have highlighted the issues and trends that...more

McDermott Will & Emery

European Health & Life Sciences Symposium 2023 | Key Takeaways

McDermott Will & Emery on

200+ leading individuals in healthcare, life sciences and private equity gathered at the Shangri-La Hotel in Paris for the European Health & Life Sciences Symposium 2023 to enjoy a day packed with fireside chats, in-depth...more

Bass, Berry & Sims PLC

Healthcare Trends & Transactions Q2 2023

Bass, Berry & Sims PLC on

The healthcare M&A market appears to be steadying. Although deal activity through the year appears slightly below the high-water marks for the corresponding period of 2022, deal activity is generally up from the first quarter...more

Knobbe Martens

Presidio Medical Raises $72 Million for ULF Neuromodulation Platform

Knobbe Martens on

Presidio Medical, Inc. announced that the company successfully concluded a Series C funding round, raising a total of $72 million. The round was led by Deerfield Management, Invus Opportunities, Action Potential Venture...more

White & Case LLP

PMB performs as pharma groups repurpose their portfolios

White & Case LLP on

After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention - Overall, pharma, medical...more

White & Case LLP

Global healthcare M&A delivers strong performance

White & Case LLP on

Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in 2021, global healthcare M&A remained robust in 2022,...more

McDermott Will & Emery

HPE Europe 2022 | Key Takeaways

McDermott Will & Emery on

Key Trends & Opportunities in Life Sciences and Healthcare Investing - The current macroeconomic environment is creating challenges for healthcare and life sciences businesses, which have been impacted hard by wage...more

McDermott Will & Emery

Antitrust M&A Snapshot - Q2 2022

McDermott Will & Emery on

APRIL – JUNE 2022: KEY THEMES AND TAKEAWAYS - UNITED STATES - • An Overview of Agency Merger Challenges from January 2021 through June 2022 Parties continue to be cautious in litigating challenged transactions. Since...more

White & Case LLP

Big pharma firms return to the deal table in H1

White & Case LLP on

Dealmaking activity in the US healthcare sector was robust in H1 2022 in the face of various macroeconomic headwinds. There were US$92.4 billion worth of deals announced in H1 2022. This was a 51 percent decrease from a...more

McDermott Will & Emery

International: Investing in Global Healthcare and Life Sciences - A guide to key legal and regulatory issues in health and life...

Today’s global healthcare marketplace is marked by unprecedented transformation. This presents both challenges and opportunity to today’s market participants. We know how important it is to structure cross-border investments...more

White & Case LLP

Sector overview: Strong M&A activity pervades nearly every sector

White & Case LLP on

Dealmakers in almost every industry had an outstandingly busy 2021. With just a few exceptions, the M&A boom swept across the US economy with deal values, in particular, up significantly on 2020 totals. Nevertheless,...more

White & Case LLP

Pharma and healthcare deliver strong results

White & Case LLP on

Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity - Healthcare and pharmaceutical deals continued at a robust pace through 2021, registering the...more

Bass, Berry & Sims PLC

Health Care Investors Conference: 2021 Recap

Bass, Berry & Sims PLC on

Bass, Berry & Sims and Deloitte presented the 2021 Health Care Investors Conference virtually on November 16... Here are some of the most significant takeaways for healthcare investors from the stimulating discussions and...more

Fenwick & West Life Sciences Group

The Most-Funded Year Ever for Digital Health Startups – New Trends, Opportunities Emerge in Q3

At the end of Q3, aggregate funding raised by digital health startups in 2021 surpassed $20 billion. Although 2021 continues to be a record-breaking year for digital health startups, investors gently tapped the breaks in Q3....more

McDermott Will & Emery

Investing in European Healthcare - What's on the Horizon for 2022? - Regulatory and Legal Changes

McDermott Will & Emery on

Today’s global healthcare marketplace is marked by unprecedented transformation. The seismic shifts in healthcare delivery and drug development during COVID-19 have, in 2021, continued to demonstrate the power and capacity...more

White & Case LLP

Healthcare displays strong deal activity post-pandemic

White & Case LLP on

The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more

McDermott Will & Emery

BVCA Healthcare Sector Forum 2020: Rounding Up

McDermott Will & Emery on

McDermott was delighted to partner with the BVCA (British Venture Capital Association) on its recent virtual Sector Forum Series: Healthcare event. The event gathered industry experts – from entrepreneurs, to investors and...more

CMCP - California Minority Counsel Program

OMNICARE and its Implications

In the spring of this year, the Supreme Court issued its long-awaited decision in Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund, 135 S.Ct. 1318 (2015), resolving a circuit split regarding the...more

23 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide